英国模型分析:Hydrus Microstent 联合白内障手术或单独用于 POAG 具成本效益
Hydrus microstent combined with cataract surgery or used alone: cost-utility analysis for UK
英国公共支付方视角的队列 Markov 模型测算显示,Hydrus Microstent 联合白内障手术相较单纯白内障手术在 15 年内多获得 0.334 个 QALY、多花费 604 英镑,ICER 为 1810 英镑/QALY。
Abstract
Background
Minimally invasive glaucoma surgery (MIGS) has the potential to become standard of care for patients with primary open angle glaucoma (POAG), whether combined with cataract surgery (CS) or as a standalone procedure. This study provides evidence of cost-effectiveness for Hydrus Microstent for both indications in UK healthcare settings.
Methods
A cohort Markov model simulated the natural history of POAG to assess costs and quality-adjusted life years (QALYs) over a 15-year horizon, comparing Hydrus Microstent + CS with CS alone, and Hydrus Microstent to iStent standalone. Patient progression across glaucoma severity health states was modelled using a rate of progression (RoP) derived from 5-year visual field loss data in HORIZON trial (for mild to moderate POAG) and by trial-based annual number of medications from COMPARE trial (for moderate POAG), respectively. Conducted from the public healthcare payer perspective, model inputs were derived from UK publicly available sources and/or publications. Both deterministic and probabilistic analyses (PA) were performed.
Results
When compared with CS alone, Hydrus + CS was estimated to generate 0.334 more QALYs but £604 higher costs over the 15-year time horizon. When comparing Hydrus to iStent, Hydrus had £534 in projected savings and generated 0.068 more QALYs. The PA showed that the probability of Hydrus + CS being cost-effective compared to CS alone is 87.6%, and about 71.5% when compared to iStent. The results were consistent across scenario analyses.
Conclusions
Hydrus implantation is a cost-effective strategy both in combination with CS (for mild-to-moderate POAG) and as a standalone procedure (for moderate POAG) in UK healthcare settings.
Introduction
In the United Kingdom, glaucoma affects approximately 4% of the population aged >50 years, most of whom (86.5%) have primary open angle glaucoma (POAG) [1] Glaucoma presents a significant patient burden and has been linked as a contributing factor to falls and fractures, road traffic accidents, loss of independence, and is the second most common cause of registered blindness in the UK [1, 2]. The estimated lifetime direct medical cost of glaucoma patient aged 50 and above in UK may reach approximately £2.57 billion [3,4,5]. A key component of this relates to ophthalmic prescribing within the NHS, where glaucoma is the most costly indication accounting to £114.2 million (2018) [6]. Falls associated with glaucoma too present a significant economic burden with annual estimates of up to £28.6 million reported to manage glaucoma-related falls [7]. It is the case that cataracts often present in a similar cohort of patients, with comorbid glaucoma occurring at rates ranging from 5.3 to 19.1% in patients undergoing cataract surgery [8,9,10].
In addition to pharmacological therapy, the historical backbone of the POAG management, the list of first line therapies has expanded [11]. Selective laser trabeculoplasty (SLT) is now recommended as the initial treatment for patients with open angle glaucoma in the UK [12]. Minimally invasive glaucoma surgery (MIGS) has been shown to significantly reduce intraocular pressure (IOP) and the need for ocular hypotensive medications [13,14,15,16]. In the UK, 73% of consultant glaucoma specialists report performing MIGS as part of their practice [17], 95% consider MIGS to offer clinical benefit and over half believe that they should be offered to all glaucoma patients [18].
MIGS devices lower IOP with a higher safety profile than conjunctival incisional/transscleral surgery addressing the treatment gap between medical therapy and more aggressive traditional surgical options. MIGS devices may be seen as more of an intermediate option before more invasive transscleral surgery is undertaken or an alternative to medical therapy to ameliorate drop burden, adherence challenges, adverse events, and quality of life (QOL) issues associated with topical medications [13]. While MIGS procedures have typically been utilised opportunistically alongside cataract surgery (CS), as 15–20% of patients undergoing CS have glaucoma [13], they have also recently been studied for standalone intervention [19]. When combined with CS, MIGS interventions occur earlier in the disease stage than would be normally considered for other traditional glaucoma surgical procedures [20].
Several MIGS devices and procedures are available for use in the UK [21]. Approved in the UK for use in conjunction with cataract surgery or as a standalone procedure, Hydrus Microstent is supported by RCT data. The Hydrus Microstent reduces IOP (HORIZON trial) and need for ocular hypotensive medication in mild to moderate open-angle glaucoma. The COMPARE study showed that in more severe glaucoma patients (i.e., baseline MD (dB): –6.2), standalone Hydrus led to significant reduction in IOP (p = 0.020) as well as in medication use at 24 months (–1.3 medications, p = 0.001) [22].
Economic studies conducted in various jurisdictions have reported that use of MIGS is cost-effective compared to other treatment options such as medical treatment, laser surgery or CS alone [23,24,25,26,27]. Economic evaluations found that MIGS seemed to offer more clinical benefit at a higher cost when compared with pharmacotherapy or when performed in combination with cataract surgery instead of cataract surgery alone. However, cost-effectiveness (CE) evidence on MIGS generated from the UK perspective is very limited [2, 28], with no head-to-head cost-effectiveness studies available for review.
The objective of this study was to generate robust evidence on the economic value of Hydrus Microstent used combined with CS compared to CS alone and standalone Hydrus compared to iStent, in patients with POAG from the UK public payer perspective.
Methods
Model structure
A cohort Markov model (Fig. 1) with 1-year cycles (with half-cycle correction) was developed in Microsoft® Excel® to compare the costs and quality-adjusted life-years (QALYs). In the base case analysis, Hydrus Microstent + CS was compared to CS alone, and in additional analysis, standalone Hydrus was compared to standalone iStent. Using data from the HORIZON and COMPARE trials, the model starts patients at baseline in the model according to the age (a mean of 71 and 67 years, respectively) and distribution of number of initial medications in these trials. Given the potentially progressive nature of glaucoma, patients were assumed to transition incrementally by 1 medication for every VFL unit of progression (1.63 dB) [29], eventually leading to secondary surgical interventions (SSxI). The model structure assumed the patient progressed through up to three (base case) or four (scenario) medications before transitioning to SSxI or increasing health state severity (e.g., mild ◄ moderate, moderate ◄ advanced). Glaucoma severity health states were defined by the Hodapp, Parish and Anderson levels validated by key opinion leaders (KOLs) and the most common criteria used by published researchers [30]. Patients did not regain visual field losses. All patients were subject to death based on UK-specific, all-cause mortality rates. The model takes the UK public healthcare payer perspective, incorporating direct medical costs. The base case model time horizon was 15 years. A discount rate of 3.5% per year was applied for all costs and effects occurring after year 1.
The figure illustrates the structure of the cohort Markov model used in the analyses.
Patient progression was informed differently for each comparison. For the combined option (i.e., Hydrus + CS vs CS alone), progression was informed by the annualised rate of progression (RoP) based on a post-hoc analysis of 5-year visual field (VFL) data from the HORIZON trial [31]. As VFL increased, a corresponding increase in medications is assumed, allowing patients to transition to the next severe health state. For the Hydrus standalone vs iStent comparison, progression was informed by trial-based annual number of medications. As patients progress on medications and VFL increases, patients transition to the next severe health state or SSxI.
As confirmed with clinical experts and published data [32], patients were assumed to add medications according to the following order in the base case: prostaglandin analogues followed by beta blocker followed by alpha agonists; carbonic anhydrase (CA) inhibitors may be used in patients who require more than three medications. The order of medications exclusively impacts costs and has no impact on IOP control or progression assumptions. Given the limited data for extrapolation from the COMPARE study, this approach is followed for both indications. SLT was not included as a part of the sequence of care in the base case. However, the impact of SLT on total costs was explored in a scenario analysis where the costs of prostaglandin analogues as #1 in the treatment sequence were replaced with SLT costs.
In the model, only patients who have had trabeculectomy are assumed at risk of going blind: blindness is set to occur with a 5.2% annual probability [33]. It is assumed that any inadequate response to treatment is accounted for with average post-treatment progression. The impact of any medication nonadherence on progression applies only to progression beyond the end of the available trial data.
Patients with vision loss are at higher risk of falling; the relative risk of falling increases with the severity of POAG. Adverse events for Hydrus and iStent and trabeculectomy complications were included in the base case [19]. Patients on two or more eye drops were assumed to be more likely to have ocular surface disease [34] which is approximated with the utility of dry eye treatment [35].
Model inputs
Clinical inputs
The model incorporated two cohorts of patients, each reflecting the trial population of HORIZON or COMPARE. It was assumed that 80% of the population in the model has bilateral disease. Bilateral treatment was assumed to affect only costs of intervention.
Patients entered the model with a starting VFL; for combined CS patients, this was –3.61 dB, the mean defect as reported in the HORIZON clinical trial, whereas it is –6.2 dB for standalone patients (COMPARE). Within the appropriate glaucoma stage (mild or moderate), patients were distributed by medication count, in accordance with HORIZON or COMPARE, depending on the evaluated cohort (Table 1).
For the Hydrus + CS vs CS only comparison, the post-hoc analysis of the 5-year HORIZON trial data determined a RoP of –0.26 dB/year for Hydrus + CS and –0.49 dB/year for CS alone. For the Hydrus vs iStent standalone comparison, transition probabilities from the COMPARE trial for both Hydrus and iStent arms were calculated (Supplementary Table 1). Given the shorter duration (24 months) of data available for COMPARE, these transition probabilities are utilised through for 60 months, after which transition probabilities are adjusted for the impact of non-adherence in scenario analyses (as described below).
For years 5 and later in the combined CS indication, the model assumes a constant progression based on 48- to 60-month probability of progression in HORIZON. HORIZON trial data shows that by the end of year 4, patients with CS are 2.9x more likely to receive SSxI. The likelihood of SSxI over time was estimated using a linear extraction for CS. The likelihood of SSxI for the Hydrus arm was estimated based on a hazard ratio (HR) of 2.9 at year 5. The patients who do not receive SSxI remain in the medication group and are subject to progression as usual.
Due to lack of adequate data to create a robust extrapolation based on COMPARE, the monotherapy indication also uses the linear progression established in HORIZON, but starting from the proportion of SSxI used by year 2 in each arm (5.30% for Hydrus patients and 13.00% for iStent patients) and from year 2 onwards.37 However, in the base case, the hazard ratios for both indications were equal to 1 (a more conservative approach), meaning that the likelihood of SSxI in the treatment arm is equal to the comparator arm after year 5 (combined CS indication) or year 2 (monotherapy indication). Of note, the reported SSxI procedures included invasive glaucoma surgery (IGS), YAG laser, CS, and stent repositioning. Scenario analysis in both evaluations is used to explore differential progression for less adherent patients.
The exploration leverages findings from Robin et al., in which 14.4% more patients on only one medication are found to be more adherent than patients on two or more medications [36]. Further, Sleath et al. find that patients who are more adherent (receive their medication 80% of the time) have an odds ratio of 0.14 for having worse VFL [37]. Based on the assumption that worse VFL can be directly attributed to differential progression (with the same magnitude of effect), the odds ratio of 0.14 is translated to a relative risk ratio using the underlying population numbers (11% less adherent, 89% more adherent) from the Sleath study, resulting in a 15.5% relative risk of progression for more adherent patients [37].
Resource use
Resource use inputs were derived from a combination of data from KOLs and published literature. For primary intervention, 80% bilateral disease was assumed based on KOL interviews [38]. Follow-up monitoring (after year 1) consisted of return appointments and tests such as optic disk imaging (ODI) and tonometry test. Patients were estimated to incur 1.5 routine appointments in mild; 2 routine appointments in moderate; 3 routine appointments in severe; and 1 routine appointment per year along with low vision services for 75% of patients in the blindness state (Table 2).
The market share across products within each drug class of the eye drops was derived based on literature [6] and KOL interviews, and were utilised to estimate annual costs of the drugs per class (Supplementary Table 2).
The rates of adverse events were obtained from the HORIZON and COMPARE trials whereas complication rates for early and late complications of trabeculectomy were derived from published literature [39]. The management of adverse events and complications were based on KOL inputs.
Cost inputs
Costs in the model were derived from various sources, including NHS National Cost Collection for physician fees and procedure costs [40], British National Formulary (BNF) [41] and Drugs and pharmaceutical electronic Market Information Tool (eMIT) [42] for medication costs. Other data sources included publications and Alcon internal data. Costs were inflated to 2023 (December) currency where needed.
Intervention costs
Medication costs are additive, and patients progress through medication classes, but if a combination therapy is chosen, the model prevents double counting of costs if an early medication class is also part of a subsequent combination. Procedure costs are provided in Table 2. iStent costs are assumed to be similar to Hydrus.
Of note, for Standalone indication, the trabeculectomy costs were derived based on the cost for the procedures the patients received as SSxI. Therefore, for the Hydrus arm (4% received CS), the cost of CS was applied whereas for the iStent arm, a weighted cost was developed (trabeculectomy (9.1%) and CS (3.9%)). Also, the trabeculectomy complications were adjusted accordingly: since no cases of glaucoma surgery, including trabeculectomy, were reported in the COMPARE trial, no costs were applied to Hydrus, while the complication costs for iStent were weighted by the proportion of patients who receive trabeculectomy (i.e., 9.1%).
Medication costs
Table 2 summarises average drug costs per year (accounted for bilateral use). The cost per bottle was multiplied by number of bottles per year to estimate the average total cost per product. Using global guidance, the model assumes 20 drops per millilitre (ML) for ophthalmic products [43] to which 21% wastage was applied, resulting in a net 15.8 drops per ML or 0.06 ML per drop [34, 44, 45]. The average cost across all formulations within the class was used as the default average cost. After trabeculectomy, patients are assumed to incur the costs of one medication (average of all medication classes) in perpetuity, reflecting 3-year data from the international Tube vs Trabeculectomy trial [46].
Other costs
The model also includes placeholders for individual costs of regular physician follow-up visits, visual field tests, falling, and both direct and indirect costs of blindness and non glaucoma cost reported in Table 2. Of note, the set of tests only includes the cost of ODI, whereas the costs of IOP and VFL tests were assumed to be included in the outpatient visit costs.
Blindness was assumed to incur the annual health care cost of visual impairment. Indirect cost of blindness was calculated considering the wage of the care giver and direct cost for blindness is calculated considering the medications, number of visits per year, i.e. 1, and proportion of blind patient on medication [24, 38]. Patients who fall has been taken into consideration as direct cost and is calculated based on the annual cost of falls in UK [7].
Utilities
The base case utility values for patients with glaucoma were derived from Burr et al. (2007). The authors reported an EQ-5D based values using UK population tariffs that were stratified by POAG severity. An alternative source of utility weights was explored in a scenario analysis: Glaucoma Utility Index (GUI) based values as reported in a cost-effectiveness analysis by Gazzard et al. 2019 [2].
Additionally, glaucoma patients who take multiple eye drops per day are more likely to experience ocular surface disease [47, 48]. KOL insight suggested that this is similar in symptoms to dry eye conditions, and therefore dry eye studies were leveraged to identify a proxy utility value for ocular surface disease. This value is applied to the proportion of patients who are expected to have ocular surface disease among patients taking two or more eye drops. Utility values and the proportion of patients with ocular surface disease while on two or more drops are captured in Table 1 below. Disutility associated with falls is also included.
Base case and analytical approach
Base case settings for both analyses and key assumptions are summarised in Supplementary Table 3. The model was run using both deterministic and probabilistic approaches. For the probabilistic approach, all parameters (i.e., ratios, probabilities, utilities, costs) are varied simultaneously to explore the universe of possible model outcomes. Each of the input parameters is considered as a random variable and drawn multiple times (e.g., 1000 iterations) from a range of values within a known distribution. The results of the probabilistic analysis (i.e. Monte Carlo simulation) were plotted on a cost-effectiveness plane to visualise the distribution of possible incremental cost-effectiveness ratios (ICER) relative to the selected comparator, as well as a cost-effectiveness acceptability curve (CEAC) to estimate the probability of a treatment strategy to be (more) cost-effective over an existing or alternative treatment strategy.
In addition to a univariate sensitivity analysis, the listed scenario analyses explored important model aspects that were hypothesised to considerably affect the CE results (Supplementary Table 4).
Results
Deterministic results
Hydrus microstent + CS vs. CS alone
Hydrus + CS is more effective, but it also is projected to incur a 2.9% higher cost when compared to CS alone. Hydrus + CS arm was associated with higher QALYs (7.620 vs 7.286 QALYs). This translated into an estimated additional 0.334 QALYs for Hydrus + CS. As there is no impact on survival, LYs are equivalent between the two strategies. At the 15-year timepoint, 6.8% of patients in the Hydrus + CS arm were estimated to require SSxI compared to 25.8% patients with CS alone. Total costs for Hydrus + CS were estimated at £21,214 vs £20,610 for CS alone, with £ 604 extra (Table 3). This resulted into an ICER of £1810 suggesting Hydrus + CS was a cost-effective treatment strategy over CS alone. Detailed results shown in Supplementary Table 5.
Hydrus standalone vs. iStent standalone
When evaluating the cost-effectiveness of Hydrus standalone compared to iStent, where intervention costs are equivalent, total projected savings were £ 534 (Table 4). Hydrus was estimated to confer slightly higher QALY gains and was dominant (i.e. less costly, more effective) over iStent alone. Patients with Hydrus were projected to remain in the moderate health state longer than patients in the iStent arm, resulting in greater QALYs, higher costs for follow-up visits but decreased costs related to SSI and blindness. Detailed results are shown in Supplementary Table 6.
Sensitivity analysis
Probabilistic sensitivity analysis
For Hydrus + CS vs. CS alone, most of the probabilistic samples (75.7%) lie in north-east (NE) quadrant of the cost-effectiveness plane where Hydrus+CS is more costly but also more effective compared with CS alone and 14.0% are in the south-east (SE) quadrant where the Hydrus+CS is less costly and more effective compared with CS alone (Supplementary Fig. 1). For Hydrus vs. iStent, most of the samples 31.5.0% lie in the NE quadrant where the Hydrus standalone is more costly but also more effective compared with iStent and 34.9% are in SE where Hydrus standalone is less costly and more effective, hence dominating iStent (Supplementary Fig. 2).
The cost-effectiveness acceptability curves (Supplementary Figs. 3 and 4) show a probability of 87.6% for Hydrus + CS being cost-effective compared with CS and a probability of 71.5% of Hydrus standalone being cost-effective compared with iStent at a willingness-to-pay (WTP) threshold of £20,000/QALY.
Scenario analyses
Scenario exploration showed that when compared against CS alone, Hydrus+ CS consistently remained cost-effective whereas, in comparison with iStent, Hydrus was a dominant treatment strategy, with 2 exceptions: Hydrus+ CS was a dominant strategy (incurred savings) from the societal perspective and Hydrus standalone was not dominant (yet cost-effective at the ICER of £ 1100) when costs of SSxI were excluded (Supplementary Table 7). Results of a univariate sensitivity analysis are available in Supplementary Figs. 5 and 6.
Discussion
From the UK public payer perspective, this model demonstrates the cost effectiveness of Hydrus Microstent both in the combined and standalone indications using the £20,000 WTP threshold. Patients experience improved quality of life, with estimated incremental QALYs of 0.334 and 0.068 compared to cataract surgery alone or iStent standalone, respectively. Hydrus Microstent was projected to incur slightly higher costs compared with CS but led to leading to cost-savings when compared with iStent, making it the preferred option.
This economic evaluation is unique for several reasons. Firstly, it includes analyses for two indications using different approaches to model patient transitions. In the standalone indication, disease progression was informed by the changes in the number of medications needed per year from the COMPARE trial. Moving to a state requiring more eye drops was assumed to indicate disease progression and was assigned a VFL loss. In the combined indication, the model leveraged VFL trial data to model patient progression. Secondly, the VFL data used for the combined indication leveraged 5-year HORIZON results, a trial with the longest follow-up in this clinical space [31], demonstrating a statistically significant reduction in the rate of VF damage progression between Hydrus + CS and CS alone.
Our findings are consistent with results of cost-effectiveness analyses conducted in other jurisdictions: studies from Canada and US indicated costs savings and higher benefits for Hydrus in both indications and for MIGS in general [23,24,25, 49, 50]. In the UK, 2 trial-based economic evaluations were reported. Gazzard (2019) [2] explored the CE of SLT versus eye drops as the first-line in the management of POAG using data collected in the LiGHT trial (3 years of follow up). The probability of SLT to be a cost-effective treatment strategy over medications was 97% at the WTP of £20 000. In comparison, Kernohan (2023) [28] compared primary surgical management compared with primary medical management in patients with advanced POAG. Although it was not surprising to see a low probability of being cost-effective at the WTP of £20 000, given the time horizon of 2 years, surgical management was associated with greater QALYs even at 2 years of follow-up. However, the authors followed up with a Markov model incorporating a lifetime horizon that showed a 73% likelihood of trabeculectomy being considered cost-effective [51].
This economic evaluation has some limitations. Patient propagation in the standalone comparison was based on 2 years of data from the COMPARE trial, which may be insufficient to capture long-term progression of patients on eye drops in real life. Additionally, patients were required to transition sequentially through up to three medications before becoming eligible for IGS. However, a proportion of patients may receive 4 medications before being offered IGS. Further, secondary surgery could include interventions other than trabeculectomy in UK. However, this type of surgery is likely to be the least expensive, hence its inclusion as the IGS is a conservative approach.
In conclusion, this economic evaluation and modelling of HORIZON and COMPARE data indicates that early use of Hydrus + CS has a high probability of being a cost-effective treatment option compared with CS alone in patients with mild to moderate POAG. When compared with iStent for use as a standalone procedure in patients with moderate disease, the probability of Hydrus being cost-effective was lower. These economic analyses can assist payers and providers in identifying the most clinically and economically prudent treatment options for patients with POAG to mitigate costs while improving patient outcomes.
Summary
What was known before:
-
Minimally invasive glaucoma surgery (MIGS) has been shown to significantly reduce IOP and the need for ocular hypotensive medications.
-
Previous economic evaluations in different jurisdictions found MIGS to be cost-effective when compared with pharmacotherapy or when performed in combination with cataract surgery instead of cataract surgery alone.
What this study adds:
-
The study provides evidence on the economic value of Hydrus Microstent used combined with CS compared to CS alone and standalone Hydrus compared to iStent, in patients with POAG from UK public payer perspective.
Data availability
Data sharing not applicable to this article as no datasets were generated or analysed during the study. The modelling conducted in the study relied on data available in the published literature.
References
Chan MPY, Broadway DC, Khawaja AP, Yip JLY, Garway-Heath DF, Burr JM, et al. Glaucoma and intraocular pressure in EPIC-Norfolk Eye Study: cross sectional study. BMJ (Clin Res ed). 2017;358:j3889.
Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet (Lond, Engl). 2019;393:1505–16.
Centre for Ageing Better. The State of Ageing in 2023 2023 [Available from: https://ageing-better.org.uk/sites/default/files/2023-12/The-State-of-Ageing-interactive-summary-2023-4.pdf.
Office of National Statistics. CT21_0003 - Age time series Census, 1981 to 2021 [Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/adhocs/14813ct210003agetimeseriescensus1981to2021.
Rahman MQ, Beard SM, Discombe R, Sharma R, Montgomery DM. Direct healthcare costs of glaucoma treatment. Br J Ophthalmol. 2013;97:720–4.
Hogg HDJ, Connor A. 10-year trends in English primary care glaucoma prescribing. Eye (Lond). 2020;34:192–6.
McGinley P, Ansari E, Sandhu H, Dixon T. The cost burden of falls in people with glaucoma in National Health Service Hospital Trusts in the UK. J Med Econ. 2020;23:106–12.
Grimfors M, Mollazadegan K, Lundström M, Kugelberg M. Ocular comorbidity and self-assessed visual function after cataract surgery. J Cataract Refract Surg. 2014;40:1163–9.
Liu Y, Congdon NG, Fan H, Zhao X, Choi K, Lam DS. Ocular comorbidities among cataract-operated patients in rural China: the caring is hip Study of Cataract Outcomes and Uptake of Services (SCOUTS), report No. 3. Ophthalmology. 2007;114:e47–e52.
Murray N, Murray T. The burden of ocular comorbidity in cataract patients in West Africa. Br J Ophthalmol. 2009;93:124–5.
Jayaram H, Kolko M, Friedman DS, Gazzard G. Glaucoma: now and beyond. Lancet (Lond, Engl). 2023;402:1788–801.
NICE. Glaucoma: diagnosis and management 2022 [Available from: https://www.nice.org.uk/guidance/ng81.
Ahmed IIK. MIGS and the FDA: What’s in a Name? Ophthalmology. 2015;122:1737–9.
Ahmed IIK, De Francesco T, Rhee D, McCabe C, Flowers B, Gazzard G, et al. Long-term outcomes from the HORIZON randomized trial for a schlemm’s canal microstent in combination cataract and glaucoma surgery. Ophthalmology. 2022;129:742–51.
Samuelson TW, Chang DF, Marquis R, Flowers B, Lim KS, Ahmed IIK, et al. A schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study. Ophthalmology. 2019;126:29–37.
Samuelson TW, Sarkisian SR Jr., Lubeck DM, Stiles MC, Duh YJ, Romo EA, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126:811–21.
Holland LJ, Kirwan JF, Mercieca KJ. Effect of COVID-19 pandemic on glaucoma surgical practices in the UK. Br J Ophthalmol. 2022;106:1406–10.
Ansari AS, Tatham AJ, Amerasinghe N, Gazzard G. Building consensus on MIGS: insights from a UKEGS survey. Eye (Lond). 2025;39:2107–9.
Ahmed IIK, Fea A, Au L, Ang RE, Harasymowycz P, Jampel HD, et al. A prospective randomized trial comparing Hydrus and iStent microinvasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: The COMPARE Study. Ophthalmology. 2020;127:52–61.
Richter GM, Coleman AL. Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol. 2016;10:189.
Examples of minimally invasive glaucoma surgery options Glaucoma UK [Available from: https://glaucoma.uk/about-glaucoma/treatments-surgery/migs.
Ang RE. 2-year results from a prospective, multicenter, randomized comparison: Hydrus vs 2 iStents for standalone treatment of glaucoma. 33rd APACRS-30th SNEC; 2021; Singapore2021.
Poitras V, Wells C, Hutnik C, Klarenback S, So H, Tsoi B, et al. CADTH Optimal Use Reports. Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment. Ottawa (ON) a user’s group panel, and from Medicus for writing articles or editorials and being on an expert panel on glaucoma management. The other authors declared no conflicts of interest relevant to this report.: Canadian Agency for Drugs and Technologies in Health Copyright ©2019 2019.
Ahmed IIK, Podbielski DW, Patel V, Falvey H, Murray J, Botteman M, et al. A Canadian cost-utility analysis of 2 trabecular microbypass stents at time of cataract surgery in patients with mild to moderate open-angle glaucoma. Ophthalmol Glaucoma. 2020;3:103–13.
Sood S, Heilenbach N, Sanchez V, Glied S, Chen S, Al-Aswad LA. Cost-effectiveness analysis of minimally invasive trabecular meshwork stents with phacoemulsification. Ophthalmol Glaucoma. 2022;5:284–96.
Cloutier L, Désy F, Nshimyumukiza L. Ponts trabéculaires iStent® et iStent inject® pour la chirurgie micro-invasive du glaucome (CMIG). Institut national d’excellence en santé et en services sociaux (INESSS); 2020.
Nieland K, Labbé A, Schweitzer C, Gicquel G, Kleintjens J, Ostawal A, et al. A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France. PLoS One. 2021;16:e0252130.
Kernohan A, Homer T, Shabaninejad H, King AJ, Hudson J, Fernie G, et al. Cost-effectiveness of primary surgical versus primary medical management in the treatment of patients presenting with advanced glaucoma. Br J Ophthalmol. 2023;107:1452–7.
Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet (Lond, Engl). 2015;385:1295–304.
Hodapp E, Parrish RK, Anderson DR. Clinical decisions in glaucoma: Mosby Incorporated; 1993.
Montesano G, Ometto G, Ahmed IIK, Ramulu PY, Chang DF, Crabb DP, et al. Five-Year Visual Field Outcomes of the HORIZON Trial. Am J Ophthalmol. 2023;251:143–55.
Rhee DJ, Sancheti H, Rothman AL, Herndon L, Brubaker JW, Patrianakos T, et al. Primary practice patterns for the initial management of open angle glaucoma. J glaucoma. 2024;33:671–8.
Saunders LJ, Russell RA, Kirwan JF, McNaught AI, Crabb DP. Examining visual field loss in patients in glaucoma clinics during their predicted remaining lifetime. Invest Ophthalmol Vis Sci. 2014;55:102–9.
Rossi GC, Pasinetti GM, Scudeller L, Radaelli R, Bianchi PE. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol. 2011;21:410–4.
Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110:1412–9.
Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533–40.
Sleath B, Blalock S, Covert D, Stone JL, Skinner AC, Muir K, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118:2398–402.
KOL Interview 2022.
Kirwan JF, Lockwood AJ, Shah P, Macleod A, Broadway DC, King AJ, et al. Trabeculectomy in the 21st century: a multicenter analysis. Ophthalmology. 2013;120:2532–9.
NHS England. 2021/22 National Cost Collection Data Publication 2024 [Available from: https://www.england.nhs.uk/publication/2021-22-national-cost-collection-data-publication/.
Joint Formulary Committee. British National Formulary (online): London: BMJ and Pharmaceutical Press; 2023 [Available from: https://www.medicinescomplete.com.
UK Government. Drugs and pharmaceutical electronic Market Information Tool (eMIT) 2023 [Available from: https://www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-information-emit.
Centers for Medicare & Medicaid Services. Pharmacy Auditing and Dispensing Job Aid: Billing other dosage forms 2015 [updated December 2015. Available from: https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Downloads/pharmacy-selfaudit-jobaid-billing-other.pdf.
Tranmer JE. et al. Valuing patient and caregiver time: a review of the literature. PharmacoEconomics. 2005;23:449–59.
Stone JL, Robin AL, Novack GD, Covert DW, Cagle GD. An objective evaluation of eyedrop instillation in patients with glaucoma. Arch Ophthalmol. 2009;127:732–6.
Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL, et al. Three-year follow-up of the tube versus trabeculectomy study. Am J Epidemiol. 2009;148:670–84.
Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418–23.
Wong ABC, Wang MTM, Liu K, Prime ZJ, Danesh-Meyer HV, Craig JP. Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye. Ocul Surf. 2018;16:289–93.
Patel V, Ahmed I, Podbielski D, Falvey H, Murray J, Goeree R. Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada. J Med Econ. 2019;22:390–401.
Ahmed IIK, Hussein I, Saheb H, Schlenker M, Schendel S, Muratov S, et al. Cost-effectiveness analysis of hydrus microstent for patients with mild to moderate primary open-angle glaucoma in Canada. Ophthalmol Glaucoma. 2015;8:302–11.
Shabaninejad H, Homer T, Kernohan A, King AJ, Burr J, Azuara-Blanco A, et al. Is primary trabeculectomy cost-effective for patients with advanced primary open angle glaucoma? Results from the Treatment of Advanced Glaucoma Study economic model. Br J Ophthalmol. 2024;108:1210–5.
Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385:1295–304.
Public Health Agency of Canada. Seniors’ Falls in Canada: SECOND Report 2014 [Available from: https://www.phac-aspc.gc.ca/seniors-aines/publications/public/injury-blessure/seniors_falls-chutes_aines/assets/pdf/seniors_falls-chutes_aines-eng.pdf.
Patino CM, McKean-Cowdin R, Azen SP, Allison JC, Choudhury F, Varma R. Group LALES. Central and peripheral visual impairment and the risk of falls and falls with injury. Ophthalmology. 2010;117:199–206.e1.
Zheng DD, Christ SL, Lam BL, Arheart KL, Galor A, Lee DJ. Increased mortality risk among the visually impaired: the roles of mental well-being and preventive care practices. Investig Ophthalmol Vis Sci. 2012;53:2685–92.
Gerlier L, Lamotte M, Verboven Y. MA3 glaucoma disease progression states: establishing a direct, quantitative link between visual field defects and utility loss. Value Health. 2010;13:A248.
Mills T, Law SK, Walt J, Buchholz P, Hansen J. Quality of life in glaucoma and three other chronic diseases: a systematic literature review. Drugs aging. 2009;26:933–50.
Boyd M, Kvizhinadze G, Kho A, Wilson G, Wilson N. Cataract surgery for falls prevention and improving vision: modelling the health gain, health system costs and cost-effectiveness in a high-income country. Inj Prev. 2020;26:302–9.
Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol. 2003;87:1201–4.
Karen Jones, Helen Louise Ann Weatherly, Sarah Birch, Adriana Castelli, Martin John Chalkley, et al. Unit Costs of Health and Social Care 2023 Manual. Technical report. Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York), Kent, UK; 2024.
Acknowledgements
We would like to acknowledge the contributions of Derek O’Boyle, Cheryl Ferrufino and Manisha Panchal to model development and reporting its results.
Funding
This study was funded by Alcon Inc.
Author information
Authors and Affiliations
Institute of Ophthalmology UCL & NIHR Biomedical Research Centre, Moorfields Eye Hospital, London, UK
Gus Gazzard
Nottingham University Hospital Academic Department of Ophthalmology, University of Nottingham Medical School, Nottingham, UK
Anthony King
Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, OH, USA
Douglas J. Rhee
University Hospitals of Cleveland, Cleveland, OH, USA
Douglas J. Rhee
IQVIA, Mississauga, ON, Canada
Faiqul Rather
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
Sergey Muratov
Authors
- Gus Gazzard
- Anthony King
- Douglas J. Rhee
- Faiqul Rather
- Sergey Muratov
Contributions
GG, AK, DJR, FR, and SM contributed to the design of the study; GG and SM contributed to the model development; GG, AK, DJR, FR, and SM contributed to the interpretation of the results, drafting the manuscript and its revisions; GG, AK, DJR, FR, and SM have approved the final version of the manuscript.
Corresponding author
Correspondence to Sergey Muratov.
Ethics declarations
Competing interests
COIs have been provided separately.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gazzard, G., King, A., Rhee, D.J. et al. Hydrus microstent combined with cataract surgery or used alone: cost-utility analysis for UK. Eye (2026). https://doi.org/10.1038/s41433-026-04970-8
Received: 10 December 2025
Revised: 17 August 2026
Accepted: 24 September 2026
Published: 21 October 2026
Version of record: 21 October 2026
DOI: https://doi.org/10.1038/s41433-026-04970-8
来源:Nature 健康护理主题 · nature.com